Hashem Taha

Investor at Vectara

Hashem Taha has a diverse work experience. In 2020, they worked as an Entrepreneur at Ankarys Therapeutics Inc, where they focused on developing stem cell-derived natural killer cell therapies. Their responsibilities included tech transfer, IP licensing, business strategy, and forming partnerships with research institutions and clinical trial centers.

In 2022, Hashem joined Vectara as part of the Go to Market team, launching the company from stealth mode with $20 million in funding. Hashem also had an Investor role at Vectara starting from January 2022.

In the same year, Hashem also took on Investor roles at various companies including Claryo, Inc., Juvena Therapeutics, Reach, NFW, Ample, and Eat Just, Inc.

Prior to these positions, Hashem worked as an Investor at TRANSFORM VC starting from January 2020, leading investments in AI/ML, novel materials, agri tech, biotech, and enterprise SaaS.

In August 2020, they became an Investor at aiXplain and also held the Go to Market & Partnerships role. Here, they launched the company from stealth mode with $3 million in funding.

Overall, Hashem Taha has demonstrated their expertise as an entrepreneur, investor, and strategist in various industries such as biotech, AI/ML, and cloud-based solutions.

Hashem Taha has a diverse education history. Hashem began their academic journey in 2010, attending the University of Toronto. Here, they pursued an Honours BSc. degree in Immunology, Drug Development, and Behavioral Psychology, which they completed in 2014 with High Distinction.

After taking a break from their studies, Hashem enrolled at the University of Toronto again in 2016. Over the next two years, from 2016 to 2018, they focused on Biomedical Engineering and obtained a MASc. degree. During this period, they gained specialized knowledge and skills in this field.

In addition to their studies at the University of Toronto, Hashem also attended New York University in 2017. Hashem took a course in Finance, specifically Advanced Valuation, which added to their academic portfolio.

Overall, Hashem Taha has a strong background in various subjects, including Immunology, Drug Development, Behavioral Psychology, Biomedical Engineering, and Finance.

Links

Timeline

  • Investor

    January 1, 2022 - present

  • Go to Market

    April, 2022